When immunotherapy meets surgery in non-small cell lung cancer

Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer

(2022) Jamie E. Chaft et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

(2022) Matthew D. Vesely et al.   Annual Review of Immunology

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

(2022) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot

(2021) Yelena Y. Janjigian et al.   CANCER CELL

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

(2021) Enriqueta Felip et al.   LANCET

Toward personalized treatment approaches for non-small-cell lung cancer

(2021) Meina Wang et al.   NATURE MEDICINE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET